Patients receiving clozapine (n=100) | All patients with schizophrenia (clozapine and non-clozapine=121) | |||
---|---|---|---|---|
Correlation coefficient | p Value | Correlation coefficient | p Value | |
Patient receiving clozapine | – | – | 0.35 | <0.001* |
Heart rate | 0.23 | 0.03* | 0.36 | <0.001* |
HDL-C level | −0.35 | <0.001* | −0.22 | 0.02* |
Triglyceride level | 0.20 | 0.04* | 0.20 | 0.03* |
Body mass index | 0.29 | 0.02* | 0.21 | 0.03* |
Diabetes | 0.19 | 0.06 | 0.19 | 0.04* |
HsCRP | 0.24 | 0.02* | 0.18 | 0.05 |
Smoking | 0.22 | 0.02* | 0.18 | 0.06 |
Neutrophil count | 0.25 | 0.01* | 0.17 | 0.06 |
Hypercholesterolaemia | 0.16 | 0.12 | 0.15 | 0.11 |
Eosinophil count | −0.03 | 0.75 | −0.15 | 0.11 |
NT-proBNP | −0.21 | 0.03* | −0.15 | 0.17 |
HbA1c | 0.18 | 0.08 | 0.14 | 0.19 |
HsTropT | 0.01 | 0.89 | 0.07 | 0.45 |
Age | 0.01 | 0.90 | 0.07 | 0.47 |
Pearson, Spearman or point-biserial correlation analysis performed based on variable type.
2D, two-dimensional; HbA1c, glycosylated haemoglobin; HDL-C, high-density lipoprotein cholesterol; HsCRP, high-sensitivity C reactive protein; HsTropT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide.